biostudies-literatureUnknown110(3)Kragh NSwedish Orphan Biovitrum<h4>Introduction</h4>The economic and clinical burden of haemophilia A is high. Primary prophylaxis with factor VIII replacement therapy is the recognised standard of care, but the emergence of non-factor therapies, such as emicizumab, is extending treatment options for people with haemophilia A.<h4>Aim</h4>There are currently no direct comparisons of efficacy or cost between recombinant factor FVIII Fc-fusion protein efmoroctocog alfa (a recombinant factor FVIII Fc-fusion protein referred to herein as rFVIIIFc) and emicizumab; therefore, a cost-effectiveness model was developed to compare prophylactic treatment with rFVIIIFc versus emicizumab in patients with haemophilia A without inhibitors in the UK.<h4>Methods</h4>The cost-effectiveness model was based on a matching-adjusted indirect cEuropean journal of haematology262-270https://www.ebi.ac.uk/biostudies/studies/S-EPMC10107896biostudies-literatureCost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.PMC10107896Pochopien MAballea STytula AKragh NToumi MBystricka LFatoye FNazir JHakimi ZfalseCost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.<h4>Introduction</h4>The economic and clinical burden of haemophilia A is high. Primary prophylaxis with factor VIII replacement therapy is the recognised standard of care, but the emergence of non-factor therapies, such as emicizumab, is extending treatment options for people with haemophilia A.<h4>Aim</h4>There are currently no direct comparisons of efficacy or cost between recombinant factor FVIII Fc-fusion protein efmoroctocog alfa (a recombinant factor FVIII Fc-fusion protein referred to herein as rFVIIIFc) and emicizumab; therefore, a cost-effectiveness model was developed to compare prophylactic treatment with rFVIIIFc versus emicizumab in patients with haemophilia A without inhibitors in the UK.<h4>Methods</h4>The cost-effectiveness model was based on a matching-adjusted indirect c2023-01-01T00:00:00Z2023 Mar2025-04-04T20:46:02.994Z2025-04-04T20:46:02.994ZS-EPMC101078963639846710.1111/ejh.13901